TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca<sup>2</sup>.

Woolums, Brian M; McCray, Brett A; Sung, Hyun; Tabuchi, Masashi; Sullivan, Jeremy M; Ruppell, Kendra Takle; Yang, Yunpeng; Mamah, Catherine et al. · Nat Commun · 2020

basic_science · Level V

Where this comes from

Abstract

The cation channel transient receptor potential vanilloid 4 (TRPV4) is one of the few identified ion channels that can directly cause inherited neurodegeneration syndromes, but the molecular mechanisms are unknown. Here, we show that in vivo expression of a neuropathy-causing TRPV4 mutant (TRPV4<sup>R269C</sup>) causes dose-dependent neuronal dysfunction and axonal degeneration, which are rescued by genetic or pharmacological blockade of TRPV4 channel activity. TRPV4<sup>R269C</sup> triggers increased intracellular Ca<sup>2+</sup> through a Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII)-mediated mechanism, and CaMKII inhibition prevents both increased intracellular Ca<sup>2+</sup> and neurotoxicity in Drosophila and cultured primary mouse neurons. Importantly, TRPV4 activity impairs axonal mitochondrial transport, and TRPV4-mediated neurotoxicity is modulated by the Ca<sup>2+</sup>-binding mitochondrial GTPase Miro. Our data highlight an integral role for CaMKII in neuronal TRPV4-associated Ca<sup>2+</sup> responses, the importance of tightly regulated Ca<sup>2+</sup> dynamics for mitochondrial axonal transport, and the therapeutic promise of TRPV4 antagonists for patients with TRPV4-related neurodegenerative diseases.

Medical subject headings